NASDAQ:SILO Silo Pharma (SILO) Stock Price, News & Analysis → The only financial event in 2024 that matters (From Porter & Company) (Ad) Free SILO Stock Alerts $2.08 +0.08 (+4.00%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$2.00▼$2.1050-Day Range$1.68▼$2.3052-Week Range$1.22▼$3.05Volume24,620 shsAverage Volume85,142 shsMarket Capitalization$5.83 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends Get Silo Pharma alerts: Email Address Silo Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside380.8% Upside$10.00 Price TargetShort InterestHealthy4.08% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 2 Articles This WeekInsider TradingAcquiring Shares$9,889 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.62 out of 5 stars 3.5 Analyst's Opinion Consensus RatingSilo Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageSilo Pharma has received no research coverage in the past 90 days.Read more about Silo Pharma's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted4.08% of the float of Silo Pharma has been sold short.Short Interest Ratio / Days to CoverSilo Pharma has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Silo Pharma has recently decreased by 26.37%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSilo Pharma does not currently pay a dividend.Dividend GrowthSilo Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SILO. Previous Next 2.8 News and Social Media Coverage News SentimentSilo Pharma has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Silo Pharma this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for SILO on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Silo Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Silo Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $9,889.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.56% of the stock of Silo Pharma is held by insiders.Percentage Held by InstitutionsOnly 5.58% of the stock of Silo Pharma is held by institutions.Read more about Silo Pharma's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioSilo Pharma has a P/B Ratio of 1.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Silo Pharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wealthpin ProTrump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house republicans called “The Key To America’s Economic Future”.You just have to make this simple move before July 30, 2024. About Silo Pharma Stock (NASDAQ:SILO)Silo Pharma. Inc., a developmental stage biopharmaceutical company, develops traditional therapeutics and psychedelic medicine. Its lead program includes SPC-15, an intranasal drug targeting post-traumatic stress disorder (PTSD) and stress-induced anxiety disorders; and SP-26, a ketamine-based loaded implant indicated for fibromyalgia and chronic pain relief. The company's preclinical products include SPC-14 to treat Alzheimer's disease; and SPU-16, a central nervous system homing peptide targeting the central nervous system with indication in multiple sclerosis. It also seeks to acquire and/or develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin and ketamine, as well as depression, mental health issues, and neurological disorders. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.Read More SILO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SILO Stock News HeadlinesMay 23, 2024 | msn.comJaguar Health, Altamira Therapeutics,Erasca among healthcare moversMay 22, 2024 | americanbankingnews.comSilo Pharma (NASDAQ:SILO) Trading Up 7.4%May 21, 2024 | globenewswire.comSilo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse PreventionMay 14, 2024 | globenewswire.comSilo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in KetamineMay 1, 2024 | msn.comMultiple sclerosis patients find hope in ‘liquid gold’April 30, 2024 | msn.com‘Liquid gold’ could bring new hope to multiple sclerosis patients, study suggests: ‘Profound benefit’April 25, 2024 | investing.comSilo Pharma reports promising SPC-15 study for PTSD therapyApril 25, 2024 | finance.yahoo.comSilo Pharma, Inc. (SILO) Stock Price, News, Quote & History - Yahoo FinanceApril 23, 2024 | finance.yahoo.comSilo Pharma Announces Positive Results for Intranasal PTSD TreatmentApril 23, 2024 | globenewswire.comSilo Pharma Announces Positive Results for Intranasal PTSD TreatmentApril 17, 2024 | msn.comPsyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & MoreApril 10, 2024 | finanznachrichten.deSilo Pharma, Inc.: Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer's Disease TherapeuticApril 10, 2024 | markets.businessinsider.comSilo Pharma Exercises Option To License AD Therapeutic SPC-14 From Columbia UniversityApril 10, 2024 | finance.yahoo.comSilo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease TherapeuticApril 10, 2024 | globenewswire.comSilo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer's Disease TherapeuticMarch 20, 2024 | finance.yahoo.comSilo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety TherapeuticMarch 18, 2024 | globenewswire.comSilo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic PainMarch 14, 2024 | finance.yahoo.comGlobal Psychedelic Drugs Market Size To Worth USD 8.7 Billion By 2033 | CAGR of 11.61%March 11, 2024 | msn.comElectoral bonds case: Supreme Court dismisses SBI’s appeal for extension of deadline, directs disclosure by March 12February 29, 2024 | morningstar.comSILO Pharma Inc SILOFebruary 28, 2024 | finanznachrichten.deSilo Pharma, Inc.: Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSDFebruary 28, 2024 | globenewswire.comSilo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSDFebruary 14, 2024 | finanznachrichten.deSilo Pharma, Inc.: Silo Pharma's SP-26 Ketamine Implant Demonstrates Successful Drug DeliveryFebruary 14, 2024 | finance.yahoo.comSilo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug DeliveryFebruary 14, 2024 | globenewswire.comSilo Pharma's SP-26 Ketamine Implant Demonstrates Successful Drug DeliverySee More Headlines Receive SILO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Silo Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today6/01/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Apparel, finished products from fabrics & similar materials Sub-IndustryN/A Current SymbolNASDAQ:SILO CUSIPN/A CIK1514183 Websilopharma.com Phone(718) 400-9031FaxN/AEmployees3Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$10.00 Low Stock Price Target$10.00 Potential Upside/Downside+380.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,700,000.00 Net Margins-4,992.30% Pretax Margin-4,895.14% Return on Equity-51.75% Return on Assets-41.59% Debt Debt-to-Equity RatioN/A Current Ratio7.87 Quick Ratio7.87 Sales & Book Value Annual Sales$72,102.00 Price / Sales80.86 Cash FlowN/A Price / Cash FlowN/A Book Value$1.89 per share Price / Book1.10Miscellaneous Outstanding Shares2,803,000Free Float2,647,000Market Cap$5.83 million OptionableNot Optionable Beta0.12 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Eric Weisblum (Age 54)Chairman, President & CEO Comp: $569.01kMr. Daniel E. Ryweck (Age 59)Chief Financial Officer Comp: $62.69kDr. James S. Kuo M.B.A. (Age 59)M.D., Vice President of Research & Development Key CompetitorsMGO GlobalNASDAQ:MGOLEver-Glory International GroupNASDAQ:EVKGLululemon AthleticaNASDAQ:LULULevi Strauss & Co.NYSE:LEVIAmer SportsNYSE:ASView All CompetitorsInsidersEric WeisblumBought 600 shares on 4/4/2024Total: $1,176.00 ($1.96/share)Eric WeisblumBought 1,100 shares on 4/1/2024Total: $2,101.00 ($1.91/share)Eric WeisblumBought 3,408 shares on 3/28/2024Total: $6,611.52 ($1.94/share)Eric WeisblumBought 500 shares on 12/19/2023Total: $815.00 ($1.63/share)Eric WeisblumBought 200 shares on 12/14/2023Total: $300.00 ($1.50/share)View All Insider Transactions SILO Stock Analysis - Frequently Asked Questions Should I buy or sell Silo Pharma stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Silo Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" SILO shares. View SILO analyst ratings or view top-rated stocks. What is Silo Pharma's stock price target for 2024? 1 analysts have issued 1-year target prices for Silo Pharma's shares. Their SILO share price targets range from $10.00 to $10.00. On average, they predict the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 380.8% from the stock's current price. View analysts price targets for SILO or view top-rated stocks among Wall Street analysts. How have SILO shares performed in 2024? Silo Pharma's stock was trading at $1.44 on January 1st, 2024. Since then, SILO shares have increased by 44.4% and is now trading at $2.08. View the best growth stocks for 2024 here. Are investors shorting Silo Pharma? Silo Pharma saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 107,200 shares, a decline of 26.4% from the April 30th total of 145,600 shares. Based on an average trading volume of 207,300 shares, the days-to-cover ratio is currently 0.5 days. Approximately 4.1% of the company's stock are short sold. View Silo Pharma's Short Interest. When is Silo Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our SILO earnings forecast. How were Silo Pharma's earnings last quarter? Silo Pharma, Inc. (NASDAQ:SILO) announced its earnings results on Monday, May, 13th. The company reported ($0.28) EPS for the quarter. The company had revenue of $0.02 million for the quarter. Silo Pharma had a negative net margin of 4,992.30% and a negative trailing twelve-month return on equity of 51.75%. How do I buy shares of Silo Pharma? Shares of SILO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SILO) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProShocking: One AI startup's revenue could surge 4,735%Manward PressMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceBill Clinton Backing Biden Replacement???The Freeport SocietyNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silo Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
